Last updated: July 28, 2026
What is Neurocrine Biosciences v. Teva Pharmaceuticals (1:21-cv-01148) about?
Neurocrine Biosciences, Inc. v. Teva Pharmaceuticals, Inc., case no. 1:21-cv-01148, is a Hatch-Waxman patent infringement dispute filed in federal court in 2021. The case centers on Teva’s FDA pathway for a Neurocrine product and the Orange Book patents listed against that product. The complaint and infringement theories drive the core business question: which listed patents Teva targeted via its ANDA filing and how Neurocrine expects to block Teva’s generic launch.
Key litigation functions in the Orange Book framework are:
- Identify the Orange Book-listed patents asserted by Neurocrine.
- Determine whether Teva’s ANDA filing is tied to a Paragraph IV certification (and which patents).
- Establish the claim construction and validity/enforceability arguments that shape the probability of a patented market exclusivity hold.
What are the asserted patents and what claims does Neurocrine allege Teva infringes?
The litigation summary for case 1:21-cv-01148 depends on two record-defined items: (1) the asserted patent list and (2) claim-by-claim infringement allegations mapped to Teva’s proposed product. Those details are not provided in the prompt, so a complete, accurate “which patents” and “what claims” analysis cannot be produced.
What court, venue, and procedural posture applies to 1:21-cv-01148?
The matter is identified by docket number 1:21-cv-01148, which indicates a U.S. federal district court civil action. A credible litigation analysis also requires:
- The filing dates for the complaint and any amended complaints.
- The scheduling order timeline (Markman dates, discovery end, dispositive motion deadlines).
- The status of claim construction, summary judgment, and trial (if any).
- Whether the parties reached a settlement or entered a consent judgment.
Those procedural facts are not included in the prompt, so the litigation posture cannot be reported without risking inaccuracies.
When did Neurocrine sue Teva and what does that imply for generic entry timing?
For Hatch-Waxman cases, filing timing is a proxy for leverage against generic launch dates. The case number indicates a 2021 filing year, but the exact service date and the specific FDA ANDA milestone (submission date and amendment cadence) determine how that timing translates into:
- The likelihood of a patent term injunction.
- The effective stay duration under 21 U.S.C. § 355(j).
- The probability of a later “launch-at-risk” posture.
Without the complaint filing date and the FDA ANDA details, timing conclusions would be speculative.
How does Paragraph IV certification factor into the dispute?
Paragraph IV certifications drive the automatic litigation trigger and stay mechanics in Hatch-Waxman. A robust analysis must tie:
- Which Orange Book patents were the subject of Teva’s Paragraph IV filing.
- Whether Teva certified to “no patent” vs. “not infringed” vs. “invalid.”
- Whether later amendments changed the certification matrix.
The prompt does not include the Paragraph IV target patents or the certification descriptions, so the Paragraph IV mechanics for this case cannot be accurately summarized.
What is the Orange Book status of the relevant Neurocrine product in this lawsuit?
Orange Book status analysis requires:
- The drug product name(s) and strength(s) implicated.
- The Orange Book patent list (US patents and expiration dates).
- Listed exclusivity (e.g., 5-year new chemical entity, 7-year new molecular entity) if applicable.
- Any pediatric exclusivity adjustments.
No Orange Book listing details are provided in the prompt; a complete status summary cannot be produced.
How strong is Neurocrine’s patent estate in this case based on typical claim types?
A high-fidelity strength assessment normally rests on three record-backed pillars:
- Claim scope and construction history (including claim construction orders).
- Validity facts (prior art citations, obviousness grounds, written description/enablement challenges).
- Enforceability defenses (inequitable conduct, prosecution history estoppel, patent ownership assignments if raised).
Because the prompt does not specify which patents or claims are involved, no accurate strength scoring can be given.
What invalidity and non-infringement defenses does Teva raise in 1:21-cv-01148?
A litigation defense map requires the parties’ filings: answer, motion to dismiss, invalidity contentions, and expert reports. The prompt does not include:
- Asserted defenses (e.g., anticipation/obviousness).
- Claim scope arguments tied to Teva’s proposed formulation, method, or dosing regimen.
- Any design-around themes that could inform launch risk.
So a defensible defense summary cannot be produced.
What does the likely outcome mean for generic entry and launch-at-risk scenarios?
Outcome mapping requires at least one of the following:
- A final judgment (non-infringement, invalidity, dismissal, summary judgment).
- A settlement with launch dates and any “carve-out” patent list.
- Consent judgment terms tied to patent expiration or earlier design-around acceptance.
Without the disposition data for 1:21-cv-01148, launch timing and at-risk likelihood cannot be stated accurately.
Have the parties settled, and if so, what are the settlement terms that control market entry?
Settlement terms typically control:
- Launch date and product carve-outs.
- Shared exclusivity timing adjustments.
- Payment or reverse-payment structure.
- Non-adjudicated dismissal terms or covenant not to sue scope.
No settlement or consent judgment details are included in the prompt. A term-level analysis cannot be provided.
What litigation documents and milestones should be reviewed for business decisions?
A complete business-grade litigation readout normally compiles:
- Complaint and exhibits (asserted patents, claim charts).
- FDA filing references (ANDA number, certification content).
- Answer and affirmative defenses.
- Scheduling order and Markman order.
- Claim construction, summary judgment motions, and any Daubert rulings.
- Pretrial order and jury verdict (if tried) or final judgment.
- Settlement agreement (if public).
Those document items and milestones are not supplied, so a record-based checklist cannot be completed.
Revenue exposure analysis: which Neurocrine revenue streams are most at risk from Teva’s ANDA?
Revenue exposure analysis requires:
- The implicated Neurocrine product and dosage forms.
- Current revenue attribution by product and by indication.
- Market share and competitor set.
- Expected generic entry dates under the specific stay and injunction mechanics.
The prompt provides no product identity. Without it, exposure cannot be quantified.
Comparative risk: how does Teva’s position in this case compare with other generic challengers?
To compare challenger risk, you need:
- Which other filers challenged the same Orange Book patents.
- Whether other defendants settled or lost on particular claims.
- Any recurring claim construction outcomes that affect all defendants.
The prompt does not include defendant group information or parallel litigation context.
Key Takeaways
- Case 1:21-cv-01148 is a Neurocrine v. Teva Hatch-Waxman-style patent infringement dispute tied to FDA pathway and Orange Book-listed patents.
- A complete litigation summary that lists asserted patents, claim theories, procedural posture, and outcome-dependent launch implications cannot be generated from the information provided.
- Any business decision on launch timing, settlement leverage, or patent strength requires the record-specific details that are not present in the prompt.
FAQs
- What patents are typically asserted in Neurocrine v. Teva Orange Book disputes?
- How does Paragraph IV certification influence the automatic stay in Hatch-Waxman cases like 1:21-cv-01148?
- What claim construction outcomes most affect generic non-infringement versus invalidity in ANDA paragraph IV litigation?
- What settlement terms usually determine generic launch date in branded-to-generic disputes?
- How do district court judgments versus PTAB outcomes change long-term patent enforcement strategy?
References
- Not provided in the prompt.
